recombin
sarscov
spike
glycoprotein
vaccin
produc
insect
cell
preclin
develop
stage
describ
truncat
version
glycoprotein
contain
ectodomain
well
histag
fulllength
version
clone
express
serumfre
insect
cell
line
expressf
protein
purifi
appar
homogen
liquid
column
chromatographi
formul
without
adjuv
g
per
dose
phosphat
salin
use
immun
mice
antigen
formul
elicit
strong
immun
respons
two
three
vaccin
antigen
neutral
antibodi
titer
correl
close
standard
elisa
reactiv
glycoprotein
truncat
protein
also
formul
adjuv
aluminum
hydroxid
g
per
dose
g
per
dose
significantli
enhanc
immun
respons
manifest
higher
titer
serum
elisa
viral
neutral
antibodi
achiev
adjuv
group
fewer
dose
lower
concentr
glycoprotein
find
indic
ectodomain
sarscov
glycoprotein
vaccin
without
adjuv
immunogen
induc
high
titer
viru
neutral
antibodi
level
similar
achiev
full
glycoprotein
vaccin
develop
sarscov
vaccin
becom
prioriti
prepared
futur
outbreak
protect
health
care
worker
manag
new
case
well
gener
popul
phase
clinic
trial
use
killedwhol
sarscov
vaccin
conduct
sinovac
biotech
ltd
howev
concern
rais
use
inactiv
viru
vaccin
base
observ
felin
coronaviru
also
sever
subunit
vaccin
preclin
develop
target
sarscov
structur
protein
includ
spike
nucleocapsid
n
protein
vaccin
candid
includ
vectorbas
dna
vaccin
combin
whole
kill
viru
dna
vaccin
inactiv
whole
viru
vaccin
combin
dna
speptid
vaccin
recombin
protein
fragment
see
front
matter
sever
acut
respiratori
syndrom
sar
respiratori
diseas
whose
main
symptom
includ
fever
cough
short
breath
pneumonia
world
health
organ
report
case
fatal
updat
recommend
octob
etiolog
agent
sar
shown
coronaviru
design
sarscov
diseas
potenti
reappear
new
natur
acquir
outbreak
accident
intentionalreleas
one
promis
candid
sarscov
protein
vaccin
glycoprotein
protein
oligom
glycoprotein
form
larg
spike
viral
envelop
mediat
bind
sarscov
host
cell
host
cell
receptor
angiotensin
convert
enzym
ii
receptorbind
domain
rbd
glycoprotein
map
residu
complex
structur
rbd
solubl
determin
protein
fragment
shown
also
induc
neutral
antibodi
glycoprotein
biochem
character
featur
explor
therapeut
applic
report
describ
two
preclin
studi
mice
use
purifi
subunit
vaccin
sar
glycoprotein
consist
ectodomain
transmembran
domain
delet
protein
histag
fulllength
glycoprotein
express
insect
cell
system
immunogen
protein
vaccin
elisa
viral
neutral
antibodi
assay
determin
togeth
adjuv
effect
aluminum
hydroxid
gene
encod
glycoprotein
clone
lysat
cultur
sarscov
passag
trizol
ls
reagent
sigma
kindli
provid
dr
dean
erdman
cdc
atlanta
briefli
cdna
clone
two
step
due
size
gene
kb
onethird
orf
front
contain
nterminu
clone
baculoviru
transfer
vector
protein
scienc
corpor
psc
downstream
baculoviru
late
promot
polyhedrin
gene
insert
also
frame
chitinas
secret
signal
sequenc
remaind
gene
clone
insert
sequenc
mwg
biotech
full
confirm
presenc
entir
gene
two
fragment
orf
join
use
conveni
restrict
site
assembl
complet
sarscov
orf
insert
flank
region
vector
sequenc
region
encod
transmembran
cytoplasm
domain
sarscov
delet
use
sitedirect
pcr
construct
name
tm
fig
assist
purif
fulllength
protein
tag
construct
cterminu
protein
fig
construct
sequenc
full
nucleotid
sequenc
ident
publish
sequenc
sarscov
gene
protein
region
gen
bank
access
gener
recombin
baculoviru
linear
autographa
california
nuclear
polyhedrosi
viru
acnpv
dna
recombin
plasmid
dna
contain
gene
mix
coprecipit
calcium
phosphat
cell
transfect
recombin
virus
identifi
distinct
plaqu
morpholog
singl
recombin
viru
plaqu
isol
viru
amplifi
use
cell
expressf
cell
absenc
serum
recombin
viru
scale
ad
liter
expressf
cell
cultur
bioreactor
multipl
infect
plaqu
form
unit
pfu
cell
infect
cultur
incub
c
h
period
recombin
sarscov
tm
protein
express
secret
recombin
baculovirusinfect
cell
histag
fulllength
glycoprotein
secret
tm
histag
fulllength
glycoprotein
purifi
appar
homogen
column
chromatographi
fig
c
formul
protein
ident
determin
ntermin
peptid
sequenc
western
blot
antihi
tag
monoclon
antibodi
qiagen
andor
antisar
sera
psc
puriti
histag
fulllength
tm
determin
densitometri
quantiti
one
densitometri
softwar
biorad
bind
protein
r
system
inc
test
standard
elisa
assay
serv
captur
molecul
antisar
monoclon
antibodi
antisera
use
detect
reagent
linear
relationship
optic
densiti
sar
protein
concentr
rang
gml
second
manuscript
detail
clone
express
purif
character
protein
prepar
prepar
vaccin
tm
protein
formul
mm
sodium
phosphat
salin
ph
four
dose
level
l
wherea
histag
fulllength
glycoprotein
formul
l
pb
use
formul
serv
vehicl
control
tabl
followup
studi
vaccin
adjuv
alhydrogel
accur
chemic
scientif
corpor
westburi
ny
tm
protein
formul
mm
sodium
phosphat
salin
ph
contain
mg
aluminumml
prepar
tm
formul
l
l
l
histag
fulllength
glycoprotein
formul
l
alhydrogel
mm
pb
pb
serv
control
tabl
nonadjuv
vaccin
prepar
store
c
adjuv
vaccin
prepar
store
c
nonadjuv
adjuv
recombin
glycoprotein
test
mice
immunogen
iit
research
institut
iitri
vaccin
prepar
administ
male
femal
mice
vafplu
charl
river
laboratori
kingston
ny
intramuscular
im
inject
accord
studi
design
shown
tabl
anim
weigh
assign
treatment
group
use
constrain
random
process
group
test
compar
pretest
bodi
weight
weight
variat
anim
use
would
exceed
mean
weight
anim
receiv
l
dose
formul
contain
grade
dose
two
antigen
prepar
day
specifi
anim
euthan
sera
collect
antitm
titer
serum
determin
elisa
briefli
plate
nuncimmuno
maxisorp
coat
gml
purifi
tm
protein
pb
incub
overnight
c
serial
twofold
dilut
mous
sera
prepar
microtit
plate
antibodi
buffer
contain
mm
nacl
tween
bsa
nonfat
dri
milk
nan
mm
trishcl
l
aliquot
serum
dilut
transfer
respect
well
coat
elisa
plate
plate
incub
c
min
color
stabil
ad
l
h
well
whose
od
monitor
multiskan
ex
plate
reader
serum
sampl
test
singlet
posit
neg
control
pool
eight
mice
respect
also
includ
elisa
plate
geometr
mean
titer
gmt
dose
bleed
day
calcul
base
titer
eight
mice
viru
neutral
vn
test
describ
perform
cell
grown
cell
cultur
plate
confluent
monolay
form
sera
heat
c
min
test
assay
duplic
sera
subject
twofold
serial
dilut
microtit
plate
pfu
sarscov
strain
tor
ad
well
prepar
incub
c
h
human
sarscov
convalesc
serum
nonimmun
human
serum
use
posit
neg
control
incub
l
serumviru
mixtur
transfer
well
incub
plate
cell
cultur
plate
contain
cell
plate
incub
c
day
plate
evalu
presenc
characterist
sarscov
cytopath
effect
cpe
neutral
titer
defin
reciproc
serum
dilut
well
immedi
well
manifest
cpe
gmt
calcul
dose
bleed
day
base
titer
obtain
eight
mice
first
studi
design
test
immunogen
recombin
sarscov
tm
glycoprotein
vaccin
mice
ectodomain
sarscov
glycoprotein
tm
produc
use
baculovirusinsect
cell
express
system
serumfre
cell
line
expressf
purifi
appar
homogen
manuscript
prepar
protein
shown
bind
solubl
r
system
inc
elisa
assay
zhou
unpublish
result
demonstr
conform
requir
function
bind
receptor
protein
formul
mm
sodium
phosphat
buffer
ph
contain
mm
nacl
dose
level
l
l
prepar
histag
fulllength
sar
glycoprotein
includ
assess
provid
insight
differ
immunogen
truncat
fulllength
protein
group
eight
mice
equal
male
femal
inject
intramuscularli
im
total
one
two
three
four
dose
everi
day
studi
day
tabl
anim
die
studi
test
materialrel
advers
clinic
sign
note
anim
gain
weight
signific
differ
bodi
weight
bodi
weight
gain
group
sera
collect
anim
test
respons
sarscov
elisa
gmt
calcul
base
serum
titer
group
bleed
day
gmt
studi
summar
tabl
tm
histag
fulllength
sar
glycoprotein
found
evok
strong
immun
respons
gmt
mice
immun
g
prepar
reach
maximum
antibodi
titer
three
immun
fig
immun
g
histag
glycoprotein
g
tm
requir
four
inject
reach
maximum
titer
g
histag
glycoprotein
group
show
similar
titer
rang
g
group
immun
tm
enhanc
immun
respons
due
dose
escal
evid
g
group
g
group
g
dose
g
dose
sera
test
sarscovneutr
antibodi
inactiv
nonspecif
neutral
factor
sera
heat
c
min
gmt
vaccin
group
bleed
day
summar
tabl
vn
test
show
antibodi
elicit
tm
histag
fulllength
spike
protein
abl
neutral
sarscov
addit
vn
antibodi
gmt
increas
increas
dose
antigen
concentr
shown
tag
tm
tm
vehicl
tm
tm
fl
histag
tm
tm
vehicl
tabl
gmt
peak
four
inject
except
g
dose
group
highest
three
inject
good
correl
antibodi
measur
elisa
vn
antibodi
tabl
suggest
elisa
may
use
surrog
measur
function
antibodi
sarscovneutr
test
avail
evalu
whether
inclus
adjuv
sarscov
prepar
would
alter
elisa
vn
titer
second
mous
immunogen
studi
perform
two
prepar
tm
l
formul
without
adjuv
al
oh
adjuv
dose
l
contain
g
aluminum
mgml
equival
g
aluminum
human
dose
due
competit
dival
cation
phosphat
al
oh
bind
phosphat
concentr
formul
buffer
reduc
mm
first
studi
mm
concentr
least
tm
g
dose
l
gml
adsorb
aluminum
hydroxid
l
mgml
data
shown
alpo
adjupho
accur
chemic
scientif
corpor
westburi
ny
also
evalu
tm
absorpt
found
less
effici
aluminum
hydroxid
bind
al
oh
data
shown
two
nonadjuv
prepar
contain
l
histag
fulllength
sar
glycoprotein
l
tm
includ
compar
perform
nonadjuv
prepar
contain
adjuv
group
eight
mice
equal
male
femal
inject
intramuscularli
im
total
one
two
three
four
dose
everi
day
studi
day
tabl
studi
one
anim
die
anoth
suffer
weight
loss
anim
high
dose
group
l
test
materialrel
advers
clinic
sign
note
signific
differ
bodi
weight
bodi
weight
gain
group
addit
signific
differ
observ
bodi
temperatur
h
follow
dose
therefor
determin
describ
event
incident
consist
normal
variat
observ
mice
biolog
signific
sera
anim
collect
end
point
titer
sera
determin
elisa
gmt
calcul
group
result
summar
tabl
gmt
six
dose
group
peak
day
four
inject
dose
respons
clearli
demonstr
fig
observ
first
studi
limit
immun
respons
observ
across
group
tabl
elisa
gmt
mous
antitm
sera
collect
second
mous
immunogen
studi
adjuv
aluminum
hydroxid
group
test
articl
dose
g
gmt
day
day
day
day
day
day
tm
tm
alum
tm
tm
alum
fl
histag
tm
alhydrogel
vehicl
alhydrogel
vehicl
primari
immun
ie
singl
dose
appear
adequ
without
use
adjuv
titer
mice
receiv
pb
control
remain
baselin
throughout
studi
adjuv
effect
al
oh
evid
across
remain
time
point
follow
second
inject
administr
adjuv
vaccin
result
gmt
sever
fold
higher
compar
correspond
nonadjuv
vaccin
instanc
adjuv
g
tm
group
titer
similar
higher
nonadjuv
g
tm
group
g
plu
alum
group
gmt
twice
high
g
group
hand
g
group
slow
immun
respons
titer
peak
late
nevertheless
titer
rang
compar
first
studi
g
histag
glycoprotein
group
also
compar
respons
histag
group
first
studi
fig
mous
sera
test
develop
sarscovneutr
antibodi
gmt
calcul
dose
group
time
point
present
tabl
highest
gmt
observ
four
inject
vaccin
group
titer
low
dose
tm
group
g
without
adjuv
peak
day
histag
fulllength
g
g
tm
group
show
highest
titer
last
time
point
day
previous
observ
gmt
measur
elisa
higher
vn
gmt
appar
aluminum
hydroxid
adjuv
group
adjuv
group
titer
severalfold
higher
correspond
nonadjuv
group
adjuv
g
tm
dose
elicit
vn
titer
close
higher
observ
nonadjuv
g
tm
group
adjuv
g
tm
dose
result
twofold
higher
vn
gmt
observ
g
group
highest
gmt
dose
group
day
overal
recombin
protein
vaccin
tm
shown
immunogen
mice
elicit
sarscovneutr
antibodi
vaccin
show
increas
antibodi
respons
increas
dose
antigen
concentr
tm
appear
perform
equival
histag
fulllength
glycoprotein
studi
adjuvant
aluminum
hydroxid
clearli
demonstr
two
differ
dose
level
g
number
studi
shown
protein
fragment
induc
sarscovneutr
antibodi
receptorbind
domain
rbd
region
play
critic
role
neutral
antibodi
induct
well
bind
viral
entri
jiang
cowork
show
rbdfc
fusion
induc
high
neutral
antibodi
titer
mice
mean
titer
sarscov
infect
deplet
rbdspecif
antibodi
sera
significantli
reduc
serumneutr
capabl
indic
domain
domin
neutral
antibodi
induct
report
sar
subunit
vaccin
histag
fulllength
tm
contain
rbd
fig
without
adjuv
shown
effect
antigen
elicit
strong
neutral
antibodi
respons
mice
encourag
sinc
highli
purifi
protein
may
poorli
immunogen
nonimmunogen
first
preclin
studi
tm
protein
vaccin
conduct
address
sever
question
includ
safeti
immunogen
abil
elicit
sarscovneutr
antibodi
dose
escal
comparison
histag
fulllength
glycoprotein
immun
respons
determin
elisa
strong
gmt
high
plateau
around
fig
sarscovneutr
antibodi
titer
averag
around
fig
within
group
gmt
increas
increas
dose
number
increas
antigen
concentr
clear
differ
observ
g
dose
g
dose
trend
evid
group
g
peak
gmt
elisa
vn
respect
valu
close
even
though
dosag
later
group
nearli
doubl
indic
immun
respons
could
improv
simpli
inject
protein
question
rais
whether
adjuv
could
enhanc
immunogen
aluminum
hydroxid
alum
introduc
frequent
use
adjuv
enhanc
immunogen
convert
solubl
protein
vaccin
particul
mass
make
suitabl
ingest
antigenpres
cell
macrophag
adjuv
potenti
aluminum
hydroxid
explor
second
mous
immunogen
studi
shown
fig
adjuv
effect
obviou
g
tm
alum
group
day
second
administr
sever
fold
differ
titer
adjuv
nonadjuv
group
similar
observ
obtain
vn
gmt
g
adjuv
dose
induc
immun
respons
equival
g
nonadjuv
dose
suggest
formul
tm
aluminum
hydroxid
result
dramat
improv
immun
respons
howev
observ
even
inclus
adjuv
multipl
dose
requir
elicit
strong
antibodi
respons
appear
strong
correl
gmt
obtain
elisa
determin
actual
vn
assay
suggest
elisa
may
use
surrog
assay
actual
vn
assay
investig
potenti
antigen
immun
respons
import
find
sinc
vn
assay
use
live
viru
must
perform
condit
henc
could
reserv
final
assess
biolog
signific
higher
gmt
observ
adjuv
antigen
alum
remain
determin
plan
conduct
sarscov
challeng
studi
ferret
studi
whether
adjuv
vaccin
inde
result
better
protect
diseas
proof
vaccin
effect
prevent
diseas
ferret
provid
valuabl
evid
plan
phase
clinic
studi
evalu
immunogen
recombin
protein
vaccin
human
subject
